IQVIA (NYSE:IQV) Price Target Raised to $196.00 at Robert W. Baird

IQVIA (NYSE:IQV - Get Free Report) had its target price boosted by research analysts at Robert W. Baird from $159.00 to $196.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price objective indicates a potential upside of 4.32% from the company's current price.

A number of other equities research analysts have also commented on the stock. Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Barclays dropped their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Finally, UBS Group decreased their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $224.05.

IQVIA Stock Performance

IQV stock opened at $187.89 on Wednesday. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The company has a 50 day moving average price of $152.90 and a 200 day moving average price of $170.50. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The stock has a market capitalization of $32.50 billion, a PE ratio of 25.60, a price-to-earnings-growth ratio of 1.88 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.64 earnings per share. Analysts forecast that IQVIA will post 10.84 EPS for the current year.

Institutional Investors Weigh In On IQVIA

Large investors have recently modified their holdings of the company. American National Bank & Trust purchased a new position in IQVIA during the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA during the 1st quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.